Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Over half the population is uninsured, and unlike consumer durables where buying decisions depend on personal research and budget, in medicines their purchase decisions hinge on what is prescribed by doctors not by free choice, Banerjee argues.
You may also be interested in...
Indian Pricing Authority Intent On Recovering Funds From Drug Companies That Allegedly Overcharged Consumers
NEW DELHI - India's drug price regulator, the National Pharmaceutical Pricing Authority, which monitors and fixes drug prices and their availability in India, has accelerated its efforts to recover $411 million that drug manufacturers have allegedly overcharged consumers for controlled drugs in the last 12 years
India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.